Optimising (re-)irradiation for locally recurrent head and neck cancer: impact of dose-escalation, salvage surgery, PEG tube and biomarkers on oncological outcomes—a single centre analysis

Table 2 Survival time analysis of prognostic parameters on OS for all patients with locoregional recurrence of head and neck squamous cell carcinoma (LR-HNSCC)

OS		N	deaths	Censored	median (CI)	p-value
UICC stage	Grade I-III	27	14	13	32 (26.05; NR)	0.003*
UICC stage	Grade IV	58	42	16	13 (10.17; 17.36)	0.003*
PEG tube	Yes	54	40	14	12 (8.93; 12.31)	0.001*
PEG tube	No	45	26	19	32 (24.45; NR)	0.001*
Salvage surgery	Yes	34	21	13	35 (16.08; NR)	0.003*
Salvage surgery	No	66	47	19	12 (8.24; 17.36)	0.003*
hsmGPS	hsmGPS 0	18	12	6	25 (12.27; NR)	0.035*
	hsmGPS 1	36	26	10	12 (9.68; 25.33)
	hsmGPS 2	4	3	1	2 (1.12; NR)
EQD2_10Gy	< 50 Gy	23	17	6	5 (2.66; 26.05)	0.012*
EQD2_10Gy	≥ 50 Gy	76	49	27	21 (12.31; 40.66)	0.012*

We performed a Kaplan–Meier analysis per category. We supplemented parameters for which proportional hazards were given with the log-rank procedure. Numbers refer to valid values. Significant results (p < 0.05) are marked with *PEG: percutaneous endoscopic gastrostomy, hsmGPS: high-sensitive modified Glasgow prognostic score, EQD2, Dose equivalent to 2 Gy; OS, overall survival; CI, confidence interval; NR, not reached

ISSN: 1748-717X